A Long Term Follow up of Results of Women undergoing an Office based Thermablate Endometrial Ablations for the Treatment of Menorrhagia

Abstract

Background: Heavy menstrual bleeding (HMB) or menorrhagia accounts for 20% of outpatient referrals to secondary gynaecological services. The Thermablate Endometrial Ablations system (EAS) is an example of a second generation of EAS used for treating menorrhagia of benign origin; reducing the necessity for a hysterectomy. The study aimed to explore long term results and success of this system’s use in an outpatient setting.

Methods: This prospective observational study examined the long term follow up of 175 women attending an outpatient setting, having a Thermablate EAS between July 2008 and July 2013. Women included had menorrhagia unresponsive to medical or hormonal therapy; and demonstrated a normal uterine cavity on hysteroscopy. They all received oral analgesia preceding ablation and welfare was ensured post procedure. Final outcomes were gathered using NOTIS; determining intervention rates following Thermablate EAS and satisfaction and improvement of quality of life through minimisation of bleeding and better symptom control.

Results: Of the 173 women, 93 women (53.7%) had lighter menstrual periods and 45 women (26%) became amenorrhoeic. 130 women (75.9%) had no interventions following Thermablate EAS. Our complication rate was 1.2%. 11 women went on to have hysterectomy for persistent uterine bleeding.

Key message: Thermablate EAS is an extremely well tolerated device ideal for use in the outpatient office setting. The long term results demonstrate high satisfaction rates and better symptom control acceptable to most women. Low intervention rate demonstrated in the form of hysterectomy has important cost implications for the NHS.

Introduction

Heavy menstrual bleeding (HMB) or menorrhagia, is defined as menstrual blood loss lasting more than 7 days over consecutive cycles, or more than 80ml per cycle [1]. This a common problem amongst premenopausal women. Such excessive loss can lead to detrimental consequences affecting all aspects of a woman’s life. Their physical health can be affected as a result of iron deficiency anaemia. HMB can also have effects on daily activities such as employment or socialising; through to the implications on emotional quality of life with issues of embarrassment, depression and problems with their sex lives [2].

It is a common gynaecological condition affecting up to 30% of women during their reproductive years and accounts for 20% of out patient referrals to secondary gynaecological services [2]. In the UK, it is likely that one in five women will undergo a hysterectomy by the age of 55 years [3]. Although a definitive treatment resulting in a menorrhea, it is not without significant risk. It has the mortality of 0.4-1.1 per 1000 operations; as well as major complications in 1 in 30 women, including anaesthetic problems, haemorrhage, pulmonary embolism, urinary retention and peripheral nerve injuries. In addition, many psychological issues can ensue such as loss of femininity and depression [4]. Of those women being treated for menorrhagia, as many as half can be found to have a normal uterus [5].

In light of this evidence, current guidelines [1,6] recommend exploring a more conservative approach initially through less invasive procedures such as endometrial ablation. The Thermablate Endometrial Ablations system (EAS) is one such example of a second generation of EAS used for treating menorrhagia of benign origin [7].

The literature has already suggested that this method is effective in achieving a menorrhea or lighter periods and so reducing the necessity for a hysterectomy [8]. The aim of this study was to explore the long term results and success of this system’s use in an outpatient setting.

Methods

This prospective observational study looked at the long term follow up of 175 women attending the Ambulatory Menstrual Disorders Clinic at the Nottingham Circle Treatment Centre. These women had a Thermablate EAS between July 2008 and July 2013.

Patients

The inclusion criteria were defined as women identified as having menorrhagia and a demonstration of unresponsiveness to conservative medical or hormonal therapy. All women were demonstrated to have a normal uterine cavity on a diagnostic hysteroscopy and endometrial biopsy and a cervical to uterine...
fungal length between 7-14 centimetres (cm). Hysteroscopy was always repeated post ablation to inspect the uterine cavity to demonstrate the integrity of the uterus and the result to the patient.

Women with malignant lesions, submucous fibroids greater than 3 cm or a history of more than three cases were an section were excluded. All women were counseled about the use of reliable contraception and that the desire to conserve fertility would be a contraindication for the use of Thermablate EAS. The women understood the procedure would be performed under a local anaesthetic in the office setting. All procedures were conducted by the same surgeon, with the assistance of two nurses.

All women had oral analgesia 2 hours preceding the Thermablate EAS in the form of 100 milligrams (mg) diclofenac and 50 mg tramadol. A perioperative intracervical block of 4% prilocaine and intracavitary 6 millilitres (ml) of 2% lidocaine were also administered. The women were discharged from the clinic post procedure usually within 30 minutes, provided they felt well and had achieved adequate pain relief. They were discharged with a supply of oral analgesia. All women received a nurse telephone consultation the day following their procedure to highlight any concerns with follow up in the outpatient clinic at 4 months.

Final outcomes were gathered using NOTIS, the hospital patient data system; to establish bleeding patterns and any further interventions required. Ethical approval was not required as the data was collected anonymously with no patients' personal data.

The primary outcome of this study was to examine the long-term results of this office based, local anaesthetic Thermablate EAS in the treatment of menorrhagia. In achieving this we also examined the intervention rates following Thermablate EAS and satisfaction and improvement of quality of life through minimization of bleeding and better symptom control.

**Results**

175 women underwent a Thermablate ablation. 2 patients did not attend their follow-up appointment and hence, were excluded from this study although no record was found on NOTIS of subsequent intervention. 20 women did not require any follow up the procedure. All women had a telephone consultation the day after and were given contact details in case of any questions or problems encountered.

Of the 173 women, 93 women (53.7%) had lighter menstrual periods and 45 women (26%) became amenorrhoeic. However, 35 women complained of unacceptable bleeding (20.2%), of whom 2.3% continued to have on-going bleeding and pelvic pain. 2 women additionally had symptoms of pelvic pain despite havings at is faction in their menstrual period (Figure 1).

Our complication rate was 1.2%. Two women had a post-operative infection, where one of them developed a haematometra. One woman became pregnant after the ablation and had a successful full-term pregnancy.

138 women (79.7%) had no interventions following Thermablate EAS. 2 women (1.2%) had non-hormonal conservative treatment, i.e. analgesia and counselling. 6 women (3.5%) had hormonal medical treatment (oral nor-ethisterone, or Gonadotrophin-releasing hormone (GnRH) analogues). 27 women into tal had surgical interventions including diagnostic laparoscopy, laparoscopic drainage of ovarian cyst, hysterectomy, hysteroscopic drainage of haematometra, trans-cervical resection of fibroid (TCRF) and trans-cervical resection of endometrium (TCRE) (Figure 2). In this group of women, 11 women went on to have hysterectomy for persistent uterine bleeding. None had a hysterectomy for abnormal endometrial pathology. The group shown to have no further interventions had a mean follow up time of 214 days. Those women requiring non-hormonal conservative treatment required the least follow up, compared to those that went on to have hormonal treatment who required the longest duration (Figure 3).

![Figure 1: Thermablate EAS Symptom Outcomes (no of women).](image1)

![Figure 2: Interventions following Thermablate Ablations (no of women).](image2)

![Figure 3: Interventions following Thermablate EA.](image3)
Discussion

The TEAS provides a valid and effective alternative therapy in those women where other choices are either contra indicated or would prove technically challenging due to an irregular uterine cavity [9,10].

It is a light weight device that employs a usable hand-held treatment control unit with a disposable fluid-filled balloon catheter system. An automatic treatment cycle involves inflation and eflation of the 13ml balloon catheter over 2minutes. Uniform destruction of the myometrium is facilitated by the therapeutic high temperature (173°Celsius) and pressure (220millimeter of mercury (mmHg)) employed. Our experience has demonstrated that the procedure is simple to perform. The short operation time and narrow catheter facilitate this, allowing it to be well tolerated. In another prospective observational study performed in our centre, Thermablate EAS appeared to be well- accepted and safe procedure for treating menorrhagia [9].

Thermablate EAS has not been as extensively reported as other balloon thermal ablation. The available studies have been in small numbers ranging from 16 to 90 patients and shorter follow-up of 6 months and up to 2 years [11-14]. Amenorrhoea rates of 25% were reported, with success rates of 80%. No major complications were reported in either study [11,12]. Our study of a larger population demonstrates a amenorrhoea rates of 26.0% and satisfaction around 80%. We have as lighter higher complication rate of 1.2% as compared to other studies [11-14]. This can be due to the higher number of cases in our studies.

There can be other cause of menorrhagia in women over 40years old other than dysfunctional uterine bleeding. Therefore, in our unit, we ensure that all the women had an endometrial biopsy prior to the TEAS treatment. Further, during hysteroscopy prior to the treatment, the endometrium is assessed for abnormal appearance before proceeding. Out of all our women, none had any abnormal uterine pathology. Other study had similar outcome with their endometrial pathology of 1.7% [14] (Figure 4).

Of the women that were treated 5% of women classified themselves from ethnic minorities with the remaining demographic of 95% classifying themselves as White British. This representation of ethnic minorities is slightly less than the national average figures in the UK [15] (Table 1).

National Institute for Health and Clinical Excellence (NICE) estimates that if all hysterectomies were to be replaced by endometrial ablation using second-generation devices, the NHS would save £32million per year. NICE concedes that his assumption is simplistic, as some women will in variably need or prefer hysterectomy [16]. Although hysterectomy is associated with longer operating time (particularly for the laparoscopic route), a longer recovery period and higher rates of postoperative complications, it offers permanent relief from heavy menstrual bleeding. Endometrial ablation offers an alternative to hysterectomy as a surgical treatment for heavy menstrual bleeding. It is effective, and satisfaction rates are high [17] (Table 2).

Table 1: Patient demographics including ethnicity.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>No. of women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age(Year); mean(range)</td>
<td>47(30-59)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>175</td>
</tr>
<tr>
<td>White British</td>
<td>164</td>
</tr>
<tr>
<td>Black Caribbean</td>
<td>2</td>
</tr>
<tr>
<td>Indian</td>
<td>2</td>
</tr>
<tr>
<td>Pakistani</td>
<td>1</td>
</tr>
<tr>
<td>Mixed: White &amp; Black Caribbean</td>
<td>2</td>
</tr>
<tr>
<td>Any other Mixed background</td>
<td>1</td>
</tr>
<tr>
<td>Any other Asian background</td>
<td>1</td>
</tr>
</tbody>
</table>

Table 2: Mean follow up duration.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>No. of days</th>
</tr>
</thead>
<tbody>
<tr>
<td>No further intervention</td>
<td>214</td>
</tr>
<tr>
<td>Amenorrhoeic</td>
<td>117</td>
</tr>
<tr>
<td>Lighter menstrual bleeding</td>
<td>267</td>
</tr>
<tr>
<td>Non hormonal conservative treatment</td>
<td>236</td>
</tr>
<tr>
<td>Hormonal treatment</td>
<td>664</td>
</tr>
<tr>
<td>Surgical intervention</td>
<td>492</td>
</tr>
<tr>
<td>Hysterectomy</td>
<td>403</td>
</tr>
</tbody>
</table>

Conclusion

Thermablate EAS is an extremely well tolerated device that is ideal for use in the outpatient office setting. The long term results demonstrate high satisfaction rates and better symptom control acceptable to most women. We have also demonstrated the low intervention rate in the form of hysterectomy, which has important cost implications for the NHS.

References


